Articles related to LUNG CANCER

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

In a sobering case from the Omaha VA Medical Center, the failure to follow up on a lung nodule resulted in a veteran’s preventable late-stage lung cancer, highlighting the imperative for rigorous oversight in patient care tracking systems.

In an alarming case at the Omaha VA Medical Center, a year-long gap in monitoring the lung imaging registry led to serious patient care oversights, including a veteran’s undiagnosed lung cancer progression. This incident highlights the critical need for continuous and vigilant monitoring in healthcare systems.

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.

UT Southwestern’s pioneering use of SCINTIX biology-guided radiotherapy represents a major advancement in precision oncology, targeting bone and lung cancers with a novel approach that combines PET imaging and radiotherapy for more effective treatment.

This study highlights repotrectinib’s remarkable efficacy in ROS1 fusion–positive NSCLC, demonstrating a notable response even in patients with the challenging ROS1 G2032R mutation, and presents a new potential standard in targeted lung cancer therapy.